The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT04632862
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 140 participants
- Registry
-
NCT04632862
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04632862. Randomized; double masking; primary purpose treatment. Start 2020-11-11 (actual); primary completion 2021-11-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- DWP16001
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct04632862- Content hash
e6f138c1727ef381c97953644a7f416163ac4fadce8f3ad9e4402fb1df8f38ca